معرفی
Howard Zhang is an Assistant Clinical Professor of Internal Medicine at Yale School of Medicine, specializing in nephrology and clinical research. His work focuses on IgA nephropathy mechanisms, complement pathway inhibition, and gut-kidney crosstalk. He contributes to Phase 3 clinical trials such as the VISIONARY trial evaluating sibeprenlimab, and the ALIGN trial studying atrasentan. Zhang has published extensively in high-impact journals like NEJM and Kidney International, with research emphasizing biomarker discovery, drug efficacy, and renal disease progression. His recent work includes analysis of Nefecon efficacy in Chinese patients and long-term safety studies. Collaborations involve global clinical networks and translational research initiatives.
Education details are not explicitly listed, but his academic role implies advanced training in medicine and nephrology. Research interests are anchored in clinical nephrology with a focus on translational studies bridging basic science and patient care. His publications reflect expertise in immunology, pharmacology, and clinical trial design.
Grants and awards are not detailed in the text, though his active involvement in multiple Phase 3 trials suggests grant-funded research. Advising roles or mentorship activities are not specified here.
